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Systematic  nonlinear  optimisation  is  a  valuable  tool  towards  evaluating  the  performance  of  conceptual
Continuous  Pharmaceutical  Manufacturing  (CPM)  ﬂowsheets.  This  study  considers  total  cost  minimisa-
tion  of  multiple  plausible  design  choices  and  eight  candidate  antisolvents  for the  continuous  recovery
of  artemisinin  (a  potent  antimalarial  Active  Pharmaceutical  Ingredient/API)  via  continuous  crystallisa-
tion,  with  simultaneous  evaluation  of process  mass  and  environmental  efﬁciency  via the  E-factor  (an
established  green  chemistry  metric).  Essential  design  variables  include  the crystallisation  cooling  tem-ontinuous Pharmaceutical Manufacturing
CPM)
onlinear Programming (NLP)
ptimisation
rystallisation
olvent selection
perature,  the  antisolvent  requirements  and  the  use  of multiple  crystallisers  in  series.  Acetonitrile  achieves
the  minimum  total  cost  for  one  crystalliser  (761  ·  103 GBP,  for a  crystallisation  at 5 ◦C, with  80%  antisol-
vent  addition  and  an  E-factor  of  29.1).  The  use  of a second  crystalliser  in  series  allows  for further  total  cost
savings  for  all  antisolvents;  E-factors  continue  to decrease  accordingly,  albeit  with  very limited  scope  for
each successive  crystalliser  due  to negligible  productivity  improvements.
©  2017  Elsevier  Ltd.  All  rights  reserved.
rtemisinin
. Introduction
Growing R&D expenditure, increasing competition from generic
anufacturers and ﬁnancial pressures on the pharmaceutical
ndustry (Fig. 1) have led to the emergence of Continuous Phar-
aceutical Manufacturing (CPM) as a promising alternative to the
urrent paradigm of batch production (Gutmann et al., 2015). While
ossessing signiﬁcant beneﬁts including equipment ﬂexibility and
xtensive industrial know-how of a mature technology, batch man-
facturing is hampered by remarkable disadvantages, including
ow efﬁciency (of both material and energy use), problematic pro-
ess scale-up and poor heat and mass transfer. The methodologies
or CPM are exceptionally beneﬁcial towards ensuring Quality by
esign (QbD), which has been fully adopted as a strategic prior-
ty by the U.S. pharmaceutical industry; moreover, they are closely
elated to the signiﬁcant instrumentation and algorithmic advances
n Process Analytical Technology (PAT), which enables unprece-
ented data acquisition and insight into pharmaceutical process
onitoring and control. Consequently, the current groundbreak-
ng developments in articulating the concepts and exploring the
oundaries of CPM, QbD and PAT have the strongest approval of
∗ Corresponding author. Tel.: +44 131 6517072.
E-mail address: D.Gerogiorgis@ed.ac.uk (D.I. Gerogiorgis).
ttp://dx.doi.org/10.1016/j.compchemeng.2017.02.046
098-1354/© 2017 Elsevier Ltd. All rights reserved.the most inﬂuential and authoritative regulatory bodies (Lee et al.,
2015).
Artemisinin is one of the most important antimalarial sub-
stances available today. First identiﬁed and isolated from the plant
Artemisia annua in the late 1970s (Tu, 2011), an accomplishment
for which the 2015 Nobel Prize in Physiology or Medicine has
been awarded, artemisinin is currently produced via batch extrac-
tion from the cultivated plant (Fig. 2). However, long product lead
times and ﬂuctuating demand due to the unpredictable burden and
outbreaks of malaria lead to highly variable prices and produc-
tion levels (Jolliffe and Gerogiorgis, 2016a). Recent research has
demonstrated the continuous synthesis of artemisinin (Kopetzki
et al., 2013; Seeberger et al., 2014). This novel synthesis route uses
a waste product from the current batch production process as a
feedstock, and produces artemisinin via two  sequential plug ﬂow
reactors (PFRs), the ﬁrst of which employs photo-oxidation. High
API product yields can be achieved, and the process has been fur-
ther adapted to produce several artemisinin derivatives (Gilmore
et al., 2014).
In recent years the continuous synthesis of a range of APIs has
been demonstrated, from common over-the-counter medications
to key anti-cancer drugs (Bana et al., 2016). However, while sig-
niﬁcant advances have been achieved in sophisticated microscale
ﬂow reactor technology, continuous separation technologies
which are also essential to combine with the former are still only
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Nomenclature and acronyms
API active pharmaceutical ingredient
ACOBC internal surface area of the COBC, m2
BLIC Battery Limits Installed Cost of all equipment in a
process, part of CapEx,  £
CapEx capital expenditure, £
Cmi concentration of species i in reactor m,  mol  L–1
Cmi0 initial concentration of species i in reactor m,
mol  L−1
CP,AS heat capacity of antisolvent, J kg–1K–1−1
CP,CW heat capacity of cooling ﬂuid, J kg–1K–1
CP,Tol heat capacity of toluene, J kg–1K–1continuous phar-
maceutical manufacturing
COBC continuous oscillatory bafﬂed reactor
CostTot total cost, the total costs over a certain plant lifetime,
adjusted to the present, £ battery-limits-installed-
cost
CPM Continuous Pharmaceutical Manufacturing
fcon factor relating the contingency to the Battery-
Limits-Installed-Cost
fCrys factor to account for non-attainment of equilibrium
in the COBC
f i summary of factors used in Eq. (16)
FOBTot (total) Free-On-Board cost of equipment
futl factor relating the cost of utilities to the total annual
requirements (kg) of material
fwas factor relating the cost of waste handling to the vol-
ume  of waste
fwc factor relating the working capital to the cost of
materials
kmi rate constant of species i, reactor m,  L mol–1 hr–1m−1
LMTD log mean temperature difference
m˙API,prod mass of API produced after separation, kg yr–1
m˙AS mass ﬂow of antisolvent in the COBC, g hr–1
mBPD mass of by-product waste, kg yr–1
mCrys,API,0 initial mole fraction of API in the COBCr
mCrys,API,f ﬁnal mole fraction of API in the COBCr
m˙CW cooling ﬂuid requirement, kg s–1
m˙Tol mass ﬂow of toluene in the COBC, g hr–1
mUAPI mass of unrecovered API, kg yr–1temperature, ◦C or
K
mur mass of unreacted reagent waste, kg yr–1
mWAS total mass of waste, kg yr–1
mWS mass of solvent waste, kg yr–1m
nAS,COBC molar ﬂow of antisolvent in the COBC, mol  hr–1
ni number (quantity) of equipment i
nTol,COBC molar ﬂow of toluene in the COBC, mol hr–1
OpEx operating expenditure, £
pi exponent used in Eq. (16)
Qm ﬂowrate through reactor m,  mL  hr–1
qCOBC cooling duty in COBC, W
RT Crys theoretical API recovery in the COBC at equilibrium
RCrys API recovery in the COBC
rmi reaction rate of molecule i in reactor m,  mol  L–1 hr–1
Ri annual requirements of material j, kg y–1
Sai reference capacity of item i, units depend on item
type
Sbi design capacity of item i, units depend on item type
T temperature, ◦C or K−1
VPFRm volume of plug ﬂor reactor m,  mL
xAPI,Crys mole fraction of API in the crystalliser
xki mole fraction of species i in stream k
Xmi conversion of species i in PFR m
Xmif Final conversion of species i in PFR
y discount rate, the correction factor for adjusting
costs to the present
˛0 Coefﬁcient used in Eq. (9)
˛1 Coefﬁcient used in Eq. (9)
˛2 Coefﬁcient used in Eq. (9)
TCOBC Temperature change from the cooling inside the
COBC
ai reference cost of item i
cont cost of contingency, £
ec factor to account for equipment engineering and
construction
ins factor to account for equipment installation
ins2 factor to account for equipment instrumentation
mat cost of material raw material purchase (including
solvents and catalysts), £
pip factor to account for equipment piping
utl cost of utilities, £
was cost of waste handling, £
wc cost of working capital, £
v˙was annual generation of waste, L y–1
 price of material j, £ kg–1TCrys temperature of crystallisation, ◦C
◦TCrys,LO cooling target temperature of crystallisation, C
UCOBC overall heat transfer coefﬁcient of the COBC, W
m–2 K–1j
 plant lifetime, years
gradually becoming available (Heider et al., 2014; Baxendale
et al., 2015; Jensen, 2017).
Process synthesis, ﬁrst-principles modelling, simulation and
cost estimation are extremely valuable methodologies for eval-
uating the beneﬁts of continuous processing in pharmaceutical
production (Gerogiorgis and Barton, 2009; Jolliffe and Gerogiorgis,
2016a,b,c, 2017; Diab and Gerogiorgis, 2017). Furthermore, system-
atic model-based optimisation has also been successfully used in
many CPM design and operation case studies (Gernaey et al., 2012;
Escotet-Espinoza et al., 2016). A relevant publication explored the
optimisation of continuous production campaigns (Sahlodin and
Barton, 2015). After studying the suitability of existing optimisa-
tion methods for continuous production lines, a novel approach
has been proposed whereby the objective function is the max-
imisation of on-spec product, as opposed to the minimisation
of start-up/shut-down time which is commonly used in higher-
volume sectors. A signiﬁcant contribution of the new approach is
that it can be efﬁciently combined with gradient-based methods,
due to the differentiability of the formulations proposed.
A recent study addressed reaction parameter estimation for a
challenging continuous ﬂow synthesis case: a nonlinear regres-
sion problem (with over 15 chemical species, 27 reactions and
29 parameters) has been formulated and solved for the optimisa-
tion of Lorcaserin synthesis, covering several key aspects of CPM
design and optimisation techniques (Grom et al., 2016). Therein,
the efﬁcient use of the Levenberg-Marquardt algorithm enabled
a computationally efﬁcient global optimisation. Another success-
ful implementation of systematic process systems engineering
methods in the ﬁeld of CPM is the optimisation of lab-scale con-
tinuous ibuprofen synthesis, with a focus on microreactor design
and operation, mass and energy balances, reaction rates and reac-
tor conﬁgurations (Patel et al., 2011); this study did not consider
API product separation, but presented a novel formulation for the
model-based minimisation of the difference between heat ﬂow to
and from the continuous ﬂow reactor.
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Fig. 1. Economic and market pressures faced by the pharmaceutical industry. (A) Typical R&D and marketing costs for a high-volume (blockbuster) pharmaceutical product.
(B)  R&D costs of various industrial sectors as a percentage of total sales. (EFPIA, 2013).
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Continuous downstream pharmaceutical processes have also
ttracted strong research interest with respect to optimisation
nd control (Ierapetritou et al., 2016; Haas et al., 2017). Surro-
ate modelling can address black-box feasibility problems: Wang
nd Ierapetritou (2017) propose a Radial Basis Function (RBF)-
ased method, expanding on previous work in which kriging
as been used to accurately determine feasible region bound-
ries (Boukouvala and Ierapetritou, 2013; Rogers and Ierapetritou,
015a,b). The proposed RBF method, which uses adaptive sampling,
an efﬁciently sample regions of high prediction uncertainty: in all
ases studied, the RBF method outperforms the previously devel-
ped kriging-based method (Wang and Ierapetritou, 2017).
Monte Carlo methods have also been use to model, predict and
ontrol crystallisation, in both stirred-tank (Kwon et al., 2014a) and
lug-ﬂow crystallisers (Kwon et al., 2014b). Protein crystal nucle-
tion, growth and dissolution have been modelled via the use of
inetic Monte Carlo (kMC) simulations, which are combined with
opulation balance equations towards describing the evolution and
ehaviour of crystal distributions within crystalliser vessels. Kwon
t al. (2014a,b) have successfully developed a model-predictive
MPC) controller to manipulate vessel jacket temperature; further-
ore, they have determined the optimal superﬁcial velocity and
roposed a novel MPC  control strategy to handle disturbances in
eed ﬂow, thus ensuring high-performance plug ﬂow crystalliser
peration (Kwon et al., 2014b).
Further case studies have also focused on the detailed mod-
lling and optimisation of downstream pharmaceutical processes,
uch as tablet formation. By considering a hybrid model-predictive
ontrol (MPC) model for moving horizon-based optimisation, Singh
t al. (2015) achieved proﬁt maximisation for a continuous tablet
ormation process which adheres to QbD principles. Furthermore,
anoﬁltration membrane cascades for solvent recovery in contin- medical formulations known as Artemisinin Combination Therapies (ACTs).
uous pharmaceutical processes has been expored via a nonlinear
optimisation formulation implemented in GAMS
®
(Abejón et al.,
2014, 2015): according to this study, total costs can indeed be sig-
niﬁcantly reduced by implementing continuous solvent recovery.
Life Cycle Assessment (LCA) studies for novel CPM processes
have employed optimisation methods as a core component of
relevant analyses (Ott et al., 2014). Systematic optimisation encom-
passing the consideration of a wide range of performance criteria
enables more advantageous process design and operation, allow-
ing for a reduction in Life Cycle Impact Assessment (LCIA) scores by
up to 45% (Ott et al., 2016). Nevertheless, the emergence of novel
pharmaceutical technologies also illustrates the pressing need for
method standardisation in order to address data gaps, as well as the
importance of consistent sensitivity analyses (Kralisch et al., 2014).
Continuous product separation and crystallisation are key unit
operations in the drive towards realizing the robust and efﬁcient
implementation of CPM. Our previous studies have explored the
potential performance of eight candidate antisolvents for contin-
uous crystallisation of artemisinin via detailed process simulation,
using both predicted and experimentally reported API solubilities
(Jolliffe and Gerogiorgis, 2016a,b). Furthermore, we have previ-
ously employed nonlinear optimisation towards identifying ideal
continuous separation designs for ibuprofen: the preferred temper-
ature, solvent and liquid–liquid extraction conﬁguration – towards
which achieve the minimum total cost for a CPM process – have
been determined via comprehensively considering plantwide mass
and molar balances, explicit reaction kinetics, parameter esti-
mation, mass transfer, thermodynamics and economic modelling
(Jolliffe and Gerogiorgis, 2017).The present study focuses on further investigating the con-
tinuous separation of artemisinin by formulating a Nonlinear
Programming (NLP) optimisation problem which simultaneously
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Fig. 3. Reaction sequence used by Kopetzki et al. (2013) for continuous artemisinin synthesis.
Fig. 4. Demonstrated process ﬂowsheet for the continuous production of artemisinin (Kopetzki et al., 2013).
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ionsiders process modelling, API solubility prediction via group
ontribution methods (UNIFAC), and environmental and sustain-
bility metrics (namely the E-factor), for several candidate API
rystallisation antisolvents. The CPM process studied here is based
n the continuous ﬂow synthesis chemistry developed recently for
rtemisinin (Kopetzki et al., 2013), which already has been shown
o be compatible with a range of separation methods (Horváth et al.,
015).
The paper is structured as follows: ﬁrst, the continuous ﬂow syn-
hesis chemistry is presented. Secondly, the continuous separation
f the API product is discussed, summarising previous contribu-
ions and illustrating how those results are used in the context of
he present research objective. This is followed by the formulation
f the nonlinear optimisation problem, and the detailed develop-
ent of the objective function the key equations encompassing
rocess modelling, product separation and economics, the neces-
ary problem constraints, and the corresponding MATLAB® code
tructure. The presentation of computational results follows, with detailed discussion of the emerging trends and their implica-
ions for technical feasibility, economic viability and environmental
mpact of the CPM plant design options evaluated.2. Process ﬂowsheet and continuous API product
separation
Numerous publications document the signiﬁcant research effort
in recent years towards producing both synthetic and semi-
synthetic artemisinin (Paddon et al., 2013; Amara et al., 2015).
The continuous synthesis route studied here is one of particular
interest, recently demonstrated by Kopetzki et al. (2013). Dihy-
droartemisinic acid (DHAA, 2) – currently routinely discarded as
waste – is transformed via intermediates to artemisinin using
photo-oxidation with subsequent acid catalysis (Fig. 3). There are
plans to commercialise this process, which has been extended to
produce various artemisinin derivatives (Gilmore et al., 2014).
2.1. Reaction system
The ﬂowsheet (Fig. 4) is based on a recent proven continu-
ous synthesis route (Fig. 3) (Kopetzki et al., 2013). Two  plug ﬂow
reactors are employed. In the ﬁrst, the key ingredient DHAA (2)
undergoes chilled photo-oxidation at −20 ◦C: it is subjected to a
monochrome light source and the addition of the photosensitising
dye, 9,10-dicyanoanthracene (DCA), which promotes the genera-
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Fig. 5. Artemisinin solubility evaluation for eight candidate continuous crystallisation antisolvents, using the UNIFAC activity coefﬁcient prediction method. Candidate
antisolvents appear in order of decreasing API solubility. The vertical axis is in mole fraction units (Jolliffe and Gerogiorgis, 2016a).
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aion of singlet oxygen. The products are key intermediate 3 and
y-products 4 and 5 (Kopetzki et al., 2013).
In the second reactor, several reactions occur simultaneously.
he key reaction sequence transforms intermediate 3 into 9
ia a Hock rearrangement, by the action of an acid catalyst
triﬂuoroacetic acid, TFA); intermediate 9 then further under-
oes oxidation with triplet oxygen to produce the API product,
rtemisinin (species 1). Other reactions occur as well, leading to fur-
her by-products (species 6 and 10)  (Kopetzki et al., 2013; Gilmore
t al., 2014).
PFR reactor design requires the calculation of the process mass
alances. Examples of relevant artemisinin CPM process mass bal-
nces at different production scales have been reported in ourrecent publications (Jolliffe and Gerogiorgis, 2016a,b,c), which have
also been based on the continuous ﬂow synthesis chemistry studied
here. Essential process modelling assumptions in order to deter-
mine plantwide mass balances prescribe that reactions occur only
inside the PFR reactors and not in any connecting process lines,
isothermal operation is ensured in all PFR reactors via sufﬁcient
heat transfer, there is no phase transformation or precipitation
affecting the ﬂow, and oxidising gas stream (oxygen) to liquid pro-
cess solvent (toluene) mass transfer does not limit the efﬁciency of
the artemisinin synthesis reaction.
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Fig. 6. Conceptual ﬂowsheet for continuous artemisinin separation via crystallisa-
tion. After API product stream concentration via solvent evaporation, a continuous
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monitoring the dimensionless numbers that describe the underly-
ing heat, mass and momentum transport phenomena underlyinghere, a CSTR-type) crystalliser is employed.
.2. Continuous API product separation
A recent paper has illustrated the implementation of process
odelling and simulation for the use of the antisolvents stud-
ed here in continuous pharmaceutical manufacturing (Jolliffe and
erogiorgis, 2016a). Eight common solvents have been investigated
s potential antisolvents for use in continuous artemisinin crystalli-
ation: ethanol (EtOH), acetone, ethyl acetate (EtOAc), methanol
MeOH), 2-propanol (2-PrOH), n-butanol (n-BuOH), butanone
methyl-ethyl ketone, MEK) and acetonitrile (ACN). Artemisinin
olubilities have been computationally evaluated for the tempera-
ure range between 0 and 40 ◦C, for toluene-to-antisolvent ratios of
0:50, 30:70, and 20:80 by weight (Fig. 5). A generalised conceptual
owsheet of the continuous separation system design is presented
n Fig. 6.
Further CPM process simulations performed under slightly
ifferent assumptions (regarding unit operation selection and
aterial requirements) illustrate the considerably varying perfor-
ance of these candidate continuous crystallisation antisolvents
Jolliffe and Gerogiorgis, 2016b) (Figs. 7 and 8 ). Ethyl acetate
nd acetonitrile are promising antisolvents, while methanol and
utanol suggest signiﬁcantly inferior performance. Based on the
odel employed by Jolliffe and Gerogiorgis (2016b), most of these
ntisolvents follow a similar trend of improving mass efﬁciency (E-
actor) with greater API recovery, with certain exceptions (Fig. 8).
here is an apparent limit to the minimum environmental impact
Fig. 7. Continuous crystallisation: simulated candidate antiemical Engineering 103 (2017) 218–232 223
(lowest E-factor) that can be attained for this conceptual continu-
ous API separation process.
These eight antisolvents have been revisited in the present tech-
noeconomic optimisation analysis, having been integrated into a
more elaborate nonlinear total cost minimisation problem formu-
lation, which again relies on our previously published API solubility
estimations. Prior to the crystallisation operation, some solvent
removal is assumed to occur, as a higher raw feed stream API
concentration is required to ensure continuous crystallisation fea-
sibility (Horváth et al., 2015). Furthermore, impurities are assumed
to not co-crystallise with the API product.
2.3. Continuous Oscillatory Bafﬂed Crystalliser (COBC)
Crystallisation via solution cooling is a commonly used unit
operation in many industries, including ﬁne chemicals and pharma-
ceuticals. Crucial process parameters towards efﬁcient puriﬁcation
and control over API crystal size distribution, morphology, and
purity are heat and mass transfer, and these become even more
important with the very high purity requirements and stringent
quality speciﬁcations which are quintessential for pharmaceuticals
(Su et al., 2015).
A remarkable recent development in crystalliser technology is
the Continuous Oscillatory Bafﬂed Crystalliser (COBC). Developed
on the basis of COB reactor technology, it combines the beneﬁts
of plug ﬂow (high-efﬁciency heat and mass transfer when static
mixing is introduced) with high throughput of the cooling crystalli-
sation operation. A COBC unit is a tubular crystalliser with regularly
spaced internal bafﬂes, which facilitate static mixing by subject-
ing the multicomponent ﬂuid stream to oscillatory ﬂow (overall,
material still ﬂows in one direction) (Lawton et al., 2009).
Despite their recent introduction in regard to commercial avail-
ability, COBC units are reported to offer excellent control for cooling
crystallisation due to their high speciﬁc surface areas (compared
to stirred tanks), and efﬁcient scalability which can be ensured bythe continuous crystallisation process in COBC systems (McGlone
et al., 2015).
solvent performance (Jolliffe and Gerogiorgis, 2016b).
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. Nonlinear optimisation problem formulation
The total cost minimisation problem is formally posed as a sum
f capital as well as time-discounted operating expenditure:
inCostTot = CapEx +
∑
t=1
{
OpEx
(1 + y)t
}
(1)
.t.
apEx = BLIC + cont + wc (2)
pEx = mat + energy + utl + was (3)
00kg yr−1 ≤ m˙API,prod (4)
◦C ≤ TCrys,LO ≤ 39◦C (5)
.5 ≤ mCrys,AS ≤ 0.8 (6)
The total CPM process cost is hence calculated by considering all
ndividual contributions to Capital Expenditure (CapEx)  and Oper-
ting Expenditure (OpEx) using Eq. (1), considering all cost items
equired to purchase, build and run a given design for a speciﬁed
ime period. In this equation  is the design lifetime (20 years) and
 is the discount rate to the present day (5%, i.e. 1.05). The capi-
al expenditure (CapEx)  consists of the Battery-Limits Installed Cost
BLIC), the cost of contingency (cont), and working capital (wc); the
perating expenditure (OpEx) consists of material purchase costs
mat), energy use costs (energy), utilities costs (util), and waste
isposal costs (was).Key constraints considered in our NLP formulation encompass
 target API production of 100 kg year–1, Eq. (4), minimum and
aximum crystallisation cooling temperatures, Eq. (5), antisolvent
omposition ranges, Eq. (6).
Fig. 9. Continuous Oscillatory Bafﬂed Crystalliser (COBC) conﬁguemical Engineering 103 (2017) 218–232
3.1. Process modelling
The NLP optimisation formulation includes all necessary equa-
tions for PFR reactor sizing, API solubility, and COBC crystalliser
design:
VPFRm = QmCmi0
∫ Xmif
0
dXmi
−rmi
(7)
rmi = kmiCmi (8)
xAPI,Crys = ˛2T2Crys + ˛1TCrys + ˛0 (9)
qCOBC = (CP,TolnTol,COBC + CP,ASnAS,COBC )TCOBC (10)
ACOBC =
qCOBC
UCOBCLMTDCOBC
(11)
m˙CW =
qCOBC
CP,CWLMTDCOBC
(12)
RTCrys =
(1 − mCrys,API,0)
(
(m˙S+m˙AS)mCrys,API,0
(1−mCrys,API,0)
)
+
(
(m˙S+m˙AS)mCrys,API,f
(1−mCrys,API,f )
)
(m˙S + m˙AS)mCrys,API,0
(1
RCrys = fCrysRTCrys (14)
PFR reactor volumes (VPFRm) are computed via the standard plug
ﬂow reactor performance equation for a ﬁrst-order reaction in reac-
tor m, using Eq. (7). Here, Q˙m is the volumetric ﬂowrate through
reactor m,  subscript i denotes the key reactant species, and Cmi00
is the initial concentration of key reactant species i in reactor m;
X is the reaction conversion, with subscript f denoting the ﬁnal
conversion.
PFR reactor sizing requires explicit knowledge of rmi, which
is the reaction rate for key reactant species i in reactor m,  and
is computed via the standard ﬁrst-order reaction rate expres-
sion, Eq. (8). The reactions for the CPM of artemisinin have been
assumed to be ﬁrst-order given the nature of the reactions (large
organic molecules reacting with an excess of smaller reagents,
e.g. O2); data has been available for these reactions, and reaction
rate constants have been estimated based on stated conversions
and lab-scale reaction line volumes, conﬁrming our reaction order
hypotheses:procedural details and results are reported in our
recent publications (Jolliffe and Gerogiorgis, 2016a,b,c).
Surrogate equations for API solubility, on the basis of Eq. (9), (Eq.
(9) have been derived from our previously computed results (Fig. 5)
which have been obtained from extensive UNIFAC simulations
(Gracin et al., 2002); these surrogate polynomial functions have
been incorporated into the NLP model that we have solved, in order
to avoid overcomplicating the nonlinear formulation (including the
circumvention of explicit UNIFAC equations in the model, which
would induce a signiﬁcantly increased computational demand).
Further details of the UNIFAC-calculated solubilities can be found
in our previous publication (Jolliffe and Gerogiorgis, 2016a). The
ration (left) and ﬂow pattern (right) (McGlone et al., 2015).
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Table  1
Surrogate equation (9) parameters for candidate continuous crystallisation antisol-
vents at three different mass concentrations.
Antisolvent Weight percent Eq. (9) parameter
˛2 ˛1 ˛0
MeOH 50 1.452 · 10−5 1.730 · 10−3 8.281 · 10−2
70 1.633 · 10−5 1.567 · 10−3 6.606 · 10−2
80 1.744 · 10−5 1.458 · 10−3 5.752 · 10−2
EtOH 50 1.617 · 10−5 1.465 · 10−3 7.538 · 10−2
70 1.832 · 10−5 1.247 · 10−3 5.564 · 10−2
80 1.984 · 10−5 1.068 · 10−3 4.430 · 10−2
PrOH 50 1.604 · 10−5 1.448 · 10−3 7.626 · 10−2
70 1.735 · 10−5 1.278 · 10−3 6.058 · 10−2
80 1.829 · 10−5 1.140 · 10−3 5.059 · 10−2
BuOH 50 1.609 · 10−5 1.413 · 10−3 7.488 · 10−2
70 1.688 · 10−5 1.269 · 10−3 6.211 · 10−2
80 1.747 · 10−5 1.153 · 10−3 5.321 · 10−2
ACN 50 1.963 · 10−5 1.545 · 10−3 4.495 · 10−2
70 2.173 · 10−5 1.238 · 10−3 3.423 · 10−2
80 2.262 · 10−5 1.056 · 10−3 2.890 · 10−2
Acetone 50 1.623 · 10−5 1.585 · 10−3 5.471 · 10−2
70 1.709 · 10−5 1.487 · 10−3 4.991 · 10−2
80 1.811 · 10−5 1.408 · 10−3 4.519 · 10−2
MEK 50 1.804 · 10−5 1.458 · 10−3 4.564 · 10−2
70 1.875 · 10−5 1.353 · 10−3 4.169 · 10−2
80 1.956 · 10−5 1.271 · 10−3 3.822 · 10−2
EtOAc 50 2.287 · 10−5 1.179 · 10−3 3.225 · 10−2
70 2.296 · 10−5 1.063 · 10−3 3.037 · 10−2
80 2.321 · 10−5 9.754 · 10−4 2.837 · 10−2
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disposal (was), which have been estimated using a subset of the
heuristics employed by Schaber et al. (2011). Utilities costs are esti-
mated on the basis of total material input, with a ﬁgure of £0.96 kg–1
used. The vast majority of waste is solvent and antisolvent, henceverage R2 value for surrogate equations used in the present study
xceeds 0.99; the parameters obtained for Eq. (9) are tabulated in
able 1, corresponding to solubility curves at 50, 70 and 80% of
eight-based antisolvent concentration (in reference to the solute-
ree solution in the crystallisation). Quadratic interpolation has
een performed as required, in order to obtain the API solubility
urves for weight percentages between the foregoing antisolvent
ass concentration values.
The energy requirement for cooling the COBC crystallisation
nits (qCOBC) has been computed via a standard homogeneous
eat transfer equation, which considers the operating tempera-
ure change and the multicomponent mixture heat capacity (Eq.
10)). This is then used in order to determine the required inter-
al surface area for heat transfer (ACOBC, Eq. (11)). Therein, UCOBC
s the overall heat transfer coefﬁcient, assumed at a conservative
alue of 100 W m−2 K−1. Moreover, LMTD is the logarithmic mean
emperature difference. The cooling medium (brine) requirement
s similarly computed via Eq. (12), where CP,CW is the heat capacity
f the brine.
The theoretically achievable API product recovery (RTCrys) is cal-
ulated from the API mole fraction solubility (mCrys,API, Eq. (13)),
hich is in turn computed from the corresponding parameterisa-
ion of surrogate API solubility Eq. (9). Further key NLP optimisation
ecision variables here are the mass of solvent (mS) and antisol-
ent (mAS) in the crystallisation unit operation(s). The actual API
ecovery is then computed from RTCrys by applying a factor (fCrys, as
er Eq. (14)) which accounts for the difference between attainable
ass transfer in regard to thermodynamic equilibrium, due to the
nevitably limited residence time implied by continuous crystalli-
ation; this crystallisation efﬁciency factor has been assumed at the
onservative value of 70%.emical Engineering 103 (2017) 218–232 225
3.2. Cost estimation
The total CPM process cost minimisation model assumes an
8040-hour (335-day) working year, for a design to be constructed
at an existing pharmaceutical facility. Both the Capital Expenditure
(CapEx) and the Operating Expenditure (OpEx) have been estimated
using publicly available commercial vendor data and established
cost estimation methods. Equipment vendor prices have been used
for process equipment if data for similar capacity is available, and
capacity-cost correlations have been used whenever such data is
unavailable (Woods, 2007).
BLIC = FOBtotins(1 + pip + ins2)(1 + ec) (15)
FOBTot =
∑
i
f iniai
(
Sbi
Sai
)pi
(16)
cont = fconBLIC (17)
wc = fwcmat (18)
mat =
∑
j
Rjj (19)
utl = futl
∑
j
Rj (20)
was = fwasv˙was (21)
The Capital Expenditure, CapEx, (2), is computed via Eq. (2) and
includes the Battery Limits Installed Cost (BLIC), the contingency
(cont) and the working capital (wc). Reference and design val-
ues for equipment are denoted by subscripts a and b, respectively.
Equipment capacities are denoted by S. These capacities are of a
dimension inherent to the equipment in question, such as volume
for a reactor, and internal area for the COBC unit. The empiri-
cal exponent p varies by equipment, and ranges between 0.1–1.0;
moreover, other factors (summarised in the multiplier fi) have
been used to account for design options (such as operating con-
ditions or construction material). The Chemical Engineering Plant
Cost Index (CEPCI) has been used to calculate the appropriate inﬂa-
tion adjustments for equipment prices as necessary, depending on
data availability.
Adjusting Eq. (16) for inﬂation produces the free-on-board
(FOB) cost. The battery-limits-installed-cBattery Limits Installed
Cost (BLIC) is then estimated via the Chilton method (Couper, 2003),
with the following factors used: the installed equipment cost ( ins)
is 1.43 times the FOB, while the process piping (pip) and instrumen-
tation ( ins22) costs are 0.3 and 0.12 times the installed equipment
costs, respectively. The total physical plant cost is the sum of the
installed, piping, and instrumentation costs, and a ﬁnal factor for
engineering and construction (ec, with a value of 0.3) has been
applied in order to compute the BLIC value. The working capital cost
(wc) has been assumed at 3.5% of annual material costs (mat), and
the contingency cost (cont) has been set at 20% of the BLIC value
(Schaber et al., 2011). Finally, the total CapEx required is the sum
of the BLIC, the working capital cost and the contingency cost, from
Eq. (2).
The Operating Expenditure (OpEx) encompasses the appreciable
cost of material purchase (mat) –, which includes raw materials,
process solvent and separation antisolvent, and is calculated using
Eq. (3). Material prices have been sourced from vendors and ofﬁ-
cial records of imports and exports to and from a wide range of
countries. The balance includes costs for utilities (utl) and waste
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cig. 10. Illustrative overview of NLP code structure for continuous artemisinin crys-
allisation (implemented in MATLAB® ).
he respective compounds are the only ones considered in order to
alculate waste handling costs (taken as £0.35 L−1).
.3. Constraints
The NLP optimisation model has been implemented in
ATLAB
®
, addressing the total process cost minimisation: each
ombination of considered antisolvent and number of crystallisers
nCOBC ) has been separately considered, in order to avoid the need
or mixed-integer (MI) formulations and preserve its conciseness.
 ≤ nCOBC ≤ 5 (22)
 ≤ xki ≤ 1∀ k, i (23)
i
xki = 1 (24)
The main decision variables are the cooling temperature which
s essential for crystalliser operation, according to Eq. (5), and
he antisolvent weight concentration in the crystallisation liquid
ixture, as per Eq. (6). The decision variables have been con-
trained within the range from which the surrogate equations
ave been derived (between 5 and 39 ◦C for crystallisation cool-
ng temperature, and between 50% and 80% for antisolvent weight
oncentration, respectively). The use of multiple crystallisers in
eries has also been studied in order to evaluate the potential for
igher API recovery: crystallisers of either ﬁxed or variable (at each
tep) volume have been considered. A maximum of ﬁve crystallisers
as been imposed, Eq. (22). A separate NLP optimisation problem
nstance has been solved for each case, in order to avoid MI  pro-
ramming formulations. The essential molar fraction constraints of
q. (23) and (24) have also been included in the NLP formulation.
.4. NLP optimisation: code structure and subroutines
The NLP optimisation code has been structured in three dis-
inct portions; a section implementing reactions and reactor sizing,
hermodynamics and product recovery equations; a section imple-
enting cost estimation equations; and a section implementing the
LP optimisation problem itself. An NLP code architecture diagrams given in Fig. 10.
The MATLAB
®
fmincon solver has been employed, using the
vailable trust-region-reﬂective method with automatic gradient
alculation. The solver has been initialised from a broad, equispacedemical Engineering 103 (2017) 218–232
grid of starting points corresponding to numerous design variable
combinations, in order to ensure that the optimal solution is unique
in each NLP problem instance, and independent of initialisation.
This initialisation grid consists of all possible (25) combinations of
antisolvent mass concentration (xCrys,AS,0, between 55% and 75%
wt., at increments of 5%) and crystallisation cooling temperature
(TCrys,LO,0, between 10 ◦C and 30 ◦C, at increments of 5 ◦C). Further-
more, the visualisation of the entire objective function (total cost)
surface for all antisolvents conﬁrms that no multiple optima should
be expected, due to its conﬁrmed and consistent convexity.
4. Results and discussion
The minimum optimal cost when considering only one crys-
talliser has been obtained for acetonitrile (ACN) at 80% wt. and
cooled to 5 ◦C, and is equal to 761·103 GBP. The total cost surfaces
are presented in Fig. 11 in order of increasing optimal cost from
the top to the bottom of the left, and then the right column (this is
the order of ascending total cost surface minima, which are at the
lowest point of each 3D colourmap). Acetonitrile (ACN) is the most
promising antisolvent because it induces the minimum total cost,
while butanol (BuOH) is the least preferable one, since it incurs the
highest total cost).
4.1. Effect of temperature, antisolvent selection and concentration
The most decisive determinant of total process cost is the cool-
ing temperature of continuous artemisinin crystallisation: despite
the cooling cost contribution to OpEx, efﬁcient cooling and lower
COBC temperatures positively affect the required CapEx,  because
they allow for smaller and cheaper COBC crystallisers, as well as
higher API recovery, which thereby requires a less expensive plant
in order to meet the target API production capacity (100 kg yr−1).
Fig. 11 presents the total cost surfaces obtained for the case of a
single COBC crystalliser and all eight candidate antisolvents; the
horizontal COBC cooling temperature axis has been restricted to a
maximum value of 25 ◦C, so as to to allow for a better visualisation
of the trends at the lower temperature end(crystallisation cooling
temperatures above 25 ◦C are not technically promising, because
the total cost increases very rapidly).
These total cost surfaces for continuous crystallisation feature
considerable variability and certain ones intersect when superim-
posed, but the most important and universal observation is that
they are consistently convex for all eight candidate antisolvents:
consequently, the global total cost minimum is attained for the
lowest cooling temperature and the highest antisolvent mass con-
centration which is technically attainable. Methanol performs very
poorly under limited cooling (high COBC temperature), but remains
more preferable in comparison to propanol and butanol in terms of
optimal cost (that is, when operating under high cooling and higher
antisolvent mass concentration). This is intuitively expectable,
because candidate antisolvents have different responses of API sol-
ubility to temperature. The antisolvents studied here as well as
previously (Jolliffe and Gerogiorgis, 2016b) have been identiﬁed
from a Pﬁzer solvent selection guide (Alfonsi et al., 2008).All but one
have been listed therein as ‘preferred’ substances: seven of the eight
feature the expected combination of process efﬁciency, safety, envi-
ronmental impact, toxicity, and other associated criteria, with the
exception of acetonitrile, which is marginally less desirable but still
classiﬁed as ‘usable’ (Alfonsi et al., 2008). While a wider spectrum of
candidate antisolventscan potentially offer improved performance
over the eight ones studied here, liquid substances which are highly
harmful or dangerous (either to human health and safety or to the
environment) have not been considered.
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tFig. 11. Total cost surfaces for a single continuous arteThe effect of antisolvent concentration on total process cost is
ess pronounced than that of cooling temperature, but it is never-
heless signiﬁcant. While the impact is more evident in Fig. 1 for
hose antisolvents which induce the highest total costs, it is clearn COBC crystalliser, in ascending minimum cost order.that higher rates of antisolvent use favourably reduce total contin-
uous crystallisation costs. An essential clariﬁcation is that the total
multicomponent content of the crystalliser remains the same, and
it is merely the proportion of raw feed solvent (toluene) to antisol-
2 nd Ch
v
c
t
i
a
(
b
c
p
p
4
e
h
m
i
t
r
s
p
c
t
s
s
s
i
c
f
c
T
r
i
j
s
c
d
t
a
t
c
s
t
f
i
a
a28 H.G. Jolliffe, D.I. Gerogiorgis / Computers a
ent that changes. Moreover, the total continuous crystallisation
ost reduction is a decreasing function of antisolvent mass concen-
ration, but at universally smaller (or even barely observable) slopes
n comparison to cooling temperature dependence, for all candidate
ntisolvents. There is an evident theoretical limit to this potential
albeit marginal) improvement, but antisolvent addition can only
e performed at ﬁnite rates: the best feasible CPM design choice for
ommercial implementation must also consider the need for com-
lete solvent removal and for prevention of concurrent impurity
recipitation (Horváth et al., 2015).
.2. Multiple crystallisers: effect on economics and
nvironmental impact
The potential use of multiple COBC crystallisers in series
as also been investigated as part of this technoeconomic opti-
isation study (Table 2, Fig. 12). Commercial crystallisation
mplementations (including current batch pharmaceutical produc-
ion processes) commonly use multiple crystallisers: it is in fact
ather uncommon for a single crystalliser to sufﬁce in order to
imultaneously meet the stringent requirements of high product
urity, high overall yield, and acceptable cost. The present study
onsiders an operation in which the mother liquor from a crys-
alliser can be concentrated, so that another crystallisation can be
ubsequently performed. Two different possibilities have been con-
idered: in the ﬁrst, all COBC crystallisers have the same size; in the
econd, the COBC crystallisers can be of variable size. Fig. 9 clearly
ndicates that there is a signiﬁcant beneﬁt when using a second
rystalliser for seven out of the eight candidate antisolvents, and
or both ﬁxed and variable sizes (naturally, when there is only one
rystalliser, the costs are the same for both ﬁxed and variable size).
he only notable exception is acetonitrile (ACN), for which the API
ecovery is such that the use of two crystallisers of the same size
nduces a total cost which is higher than the case of employing
ust one; however, for crystallisers of variable size, two crystalli-
ation units are optimal for acetonitrile (ACN). Employing COBC
rystallisers of variable size may  seem an obvious and intuitive
esign objective, but our purpose here is the precise and compara-
ive evaluation of projected beneﬁts for all antisolvents, COBC sizes
nd operational conﬁgurations. The expected beneﬁt computed on
he basis of our NLP optimisation model for continuous artemisinin
rystallisation is in the order of 50 · 103 GBP; accordingly, there is a
trong incentive to use COBC units of variable size, in comparison
o the respective crystallisers of ﬁxed size.
The E-factor, ﬁrst used by Sheldon (2012), is a versatile and use-
ul green chemistry metric. The simplest deﬁnition of the E-factor
s the quantity of waste generated per unit mass of product: values
s high as 200 are common for pharmaceutical processes, which
re predominantly batch operations; conversely, highly efﬁcient
Fig. 12. Optimal total costs for multiple COBC crystallisers (squares: ﬁemical Engineering 103 (2017) 218–232
industries which rely on continuous production methods (such as
oil and gas extraction and reﬁning) enjoy remarkably low E-factors
in the order of 0.1, indicating extremely high mass efﬁciency and
consequently very low waste generation (Ritter, 2013). The present
study employs the foregoing E-factor deﬁnition according to Eq.
(25), in which the environmental impact metric is computed on
the basis of pure recovered API product, while the waste consists of
byproducts (BPD), unconverted reactants (UR), waste solvent (WS,
10% of the total quantity has been assumed unrecoverable), waste
antisolvent (WAS, all assumed unrecoverable) and unrecovered API
(UAPI):
E-factor = mWaste
mAPI
= mBPD + mUR + mWS + mWAS + mUAPI
mAPI
(25)
The E-factorhas not been included as an explicit objective term
or constraint in the NLP optimisation problem formulation. The
respective values for all continuous crystallisation cases and COBC
conﬁgurations have been computed in order to gain a more detailed
understanding of the optimised costs, so as to further evaluate the
interplay between process efﬁciency, economic viability and envi-
ronmental impact of this (and similar) conceptual CPM processes.
The E-factor continues to improve when using more crystallisers
of variable size, at least up to the upper bound (5) considered here,
in contrast to the respective total process cost trend (Fig. 11). For
a single crystalliser, the use of butanol results in the highest E-
factor, and the use of acetonitrile in the lowest. The order for the
E-factors here (for one crystalliser) is identical to the order of total
costs. This order changes with the use of more crystallisers: when
using four or ﬁve crystallisers of ﬁxed size, ethanol (not butanol)
has the highest and least attractive E-factor. For some antisolvents,
most apparently for ethyl acetate, E-factors for a series of ﬁxed-
size crystallisers begin to increase for four or more crystallisers;
this effect is due to the relatively greater quantities of antisolvent
required for the amount of API recovered (Fig. 13).
The general improvement in E-factor (the decreasing trend evi-
dent in Fig. 13 due to the use of more crystallisers) is achieved
because of increasing plantwide API product recovery efﬁciency,
according to Eq. (25). An increased number of crystallisers enables
additional (secondary, tertiary, quaternary or even quinary) API
product recovery, thereby reducing the numerator and simulta-
neously increasing the denominator in the E-factor deﬁnition. The
biggest improvement is achieved when expanding from one to two
COBC crystallisers, and each further expansion incurs a less signif-
icant improvementwhich therefore limits the scope of increasing
the continuous separation plant size: the increase in total cost from
two to three (or more) crystallisers is unlikely to be justiﬁed by
additional incremental E-factor improvements, as the latter are not
combined with appreciable efﬁciency improvements.
xed volume crystallisers; circles: variable volume crystallisers).
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Table  2
Key NLP optimisation results for total process cost and environmental impact (E-factor).
Antisolvent Optimal total cost (103 GBP) Fig. 11, max  (103 GBP) API recovery (%) E-factor (min)
1 crystalliser 2 crystallisersa 1 (5) crystallisers
ACN 761 707 1824 58.08 29.1 (17.6)
EtOAc 791 751 1508 58.05 29.6 (18.1)
MEK  837 775 1866 53.76 32.6 (17.9)
Acetone 852 762 2146 50.52 33.9 (18.4)
EtOH  888 785 3016 35.31 35.3 (18.4)
MeOH 917 768 3546 43.95 37.7 (17.8)
PrOH  949 837 2977 45.51 37.9 (19.3)
BuOH 978 862b 2851 44.40 39.5 (19.2)
a Optimal number of crystallisers.
b 3 crystallisers is optimal for BuOH.
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.3. Crystalliser size
The required COBC crystalliser volumes vary signiﬁcantly as a
unction of the candidate antisolvent and the maximum number of
quipment units allowed, as can be seen in Fig. 11: although the
OBC crystalliser volume trend does not exactly follow the order of
otal costs, there are remarkable observations: butanol (BuOH) is
he least preferable antisolvent, because it incurs the highest total
ost minimum and requires the largest COBC crystalliser volume for
 single equipment unit. Acetonitrile (ACN) is the most preferable
ntisolvent, because it achieves the lowest total cost minimum, as
 result of the second lowest COBC crystalliser volume required.
he differences arise from the thermodynamic characteristics of
he antisolvents, which determine cooling requirements and costs.
ith the use of more crystallisers, COBC unit sizes decrease: for a
iven antisolvent, the size of crystalliser number n in the series is
maller when more crystallisers are being used overall. Moreover,
he decrease in COBC size is greatest initially, when moving from
ne to two crystallisers, and this is clearly reﬂected in total cost
rends: indeed, for more than two COBC crystallisers in series, the
otal cost increases, rendering any further expansion economically
isadvantageous.
For a single crystalliser, there is obviously no difference in using
xed or variable size COBC crystallisation units. In several of the
ntisolvent/number of crystalliser cases considered, the size of the
xed crystalliser is very similar to the ﬁrst in the correspond-
ng series of variable-volume crystallisers (e.g. the alcohols, two
rystallisers). For other cases (three or more crystallisers), the ﬁxed-
ized COBC units are smaller than the ﬁrst, but larger than the
ubsequent variable-volume crystallisers.
The sizes of COBC crystallisers are determined on the basis of
eat transfer requirements, given the extreme scarcity of crystal
rowth kinetics for the API-solvent-antisolvent systems considered
ere; their computational determination also relies on corre-ares: ﬁxed volume crystallisers; circles: variable volume crystallisers).
sponding lab-scale batch crystallisers (Horváth et al., 2015). For
commercial implementation, there are important considerations
for crystal size distribution and morphology, which are strictly
speciﬁed by pharmaceutical product regulations (Desiraju and
Nangia, 2016). For further design and analysis towards indus-
trial implementation, comprehensive experiments elucidating
artemisinin crystal growth kinetics and mechanisms are required
(Malwade et al., 2013, 2016). The use of COBC units promises sig-
niﬁcant beneﬁts, as it has been reported to offer excellent control
over crystal formation and growth (McGlone et al., 2015) (Fig. 14).
By the ﬁfth crystalliser, the quantities of material processed are
very small, leading to low heat transfer requirements and small
volumes. Notwithstanding the likely design hurdles in operating
COBC crystallisation units at this size, the clear conclusion is that
the optimal cost in most cases is achieved for no more than two
COBC crystallisers. The optimal choiceis therefore to use acetoni-
trile (ACN) or ethyl acetate (EtOAc), to mitigate environmental
impact, as antisolvent, and a system of twoCOBC crystallisers in
series of sequentially decreasing size, operating at a crystallisa-
tion cooling temperature of 5 ◦C, with the use of an 80% antisolvent
(acetonitrile) mass concentration (solute-free basis).
4.4. Maintenance and operability considerations
Maintenance and operability are crucial considerations in order
to ensure a rapid and smooth transition from the conceptual and
laboratory process R&D stages to commercial implementation.
While continuous manufacturing requires less cleaning than batch
operations (due in large part to the inherent requirements of batch
processing, as well as its multi-purpose nature) and can operate
for long periods without scheduled maintenance shutdowns, con-
tinuous processing equipment tends to be more complex than the
respective batch processing units. Furthermore, the construction,
installation, operation and maintenance of COBC crystalliser units
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nterpretation of the references to colour in this ﬁgure legend, the reader is referred
f very small volume and/or internal diameter may  be prohibitively
mpractical for commercial implementation - this is a point which
llustrates that technical efﬁciency and economic viability is scale-
ependent, and a strong function of plant capacity. Consequently,
aintenance and operability costs and their variation between sin-
le and multiple crystallisers, and between multiple crystallisers of
xed volume (equally sized crystallisers in series) and variable vol-
me  (crystallisers in series of sequentially decreasing volume) are
ssential in order to further elaborate on the comparative technoe-
onomic evaluation of potential continuous COBC crystallisation
ersus batch crystallisation implementations.. While COBC crys-
allisation units rely on plug ﬂow theirbafﬂes and oscillating ﬂow
attern are reliable safeguards against potential blockage.
.5. Wider applicability of employed methods
The present study employs a wide spectrum of established
rocess systems engineering methods, including kinetic param-
ter and thermophysical property estimation, estimation of
PI solubilities via group contribution (UNIFAC) methods, and
ost importantly economic evaluation and environmental impact
ssessment within the framework of a nonlinear optimisation
roblem, towards achieving total cost minimisation for a continu-
us pharmaceutical process. Traditionally, batch operation is vastly
ore prevalent in the pharmaceutical industry. The methods and
ramework used here could be adapted for a batch process instead,
nd methods used in the present study have indeed been employed
n technoeconomic evaluations of both batch and continuous pro-
esses (Schaber et al., 2011; Heider et al., 2014; Ott et al., 2016).
o extend the current systematic NLP optimisation methodology
or implementation in a respective batch process, the presented
ormulation would have to be signiﬁcantly augmented: the result-
ng model must encompass all technical features of the respectiveentical volumes, coloured bars indicate a series of COBCs of varying volumes. (For
e web version of this article.)
unit operations, but most importantly the operational aspects of
production vs. maintenance and idle time, in order to ensure a
fully elucidated (hence fair) comparison, on a realistic and suitably
justiﬁed basis.
5. Conclusions
The present paper presents the detailed technoeconomic pro-
cess modelling and investigation of eight candidate antisolvents
for the systematic optimisation of continuous artemisinin recov-
ery via cooling COBC crystallisation. The NLP problem formulation
addresses total cost minimisation for a 20-year design lifetime,
and simultaneously explores process mass efﬁciency and environ-
mental impact, which is evaluated in terms of E-factor (a widely
used green chemistry metric). Key process decision variables are
the continuous crystallisation cooling temperature, and the nature
and mass concentration of the crystallisation antisolvent; the use of
multiple crystallisers in series has been also investigated in order to
elucidate the potential for total cost and mass efﬁciency improve-
ments.
Eight antisolvents have been identiﬁed and studied here, on
the basis of a solvent selection guide published recently (Alfonsi
et al., 2008). Acetonitrile presents the best continuous crystalli-
sation option, achieving the lowest minimum total cost for one
crystalliser out of all candidate antisolvents (761 · 103 GBP, for a
crystallisation at 5 ◦C, with 80% antisolvent addition and an E-factor
of 29.1). The use of additional COBC crystallisers in series allows an
improvement in total cost: this occurs up to the use of two crys-
tallisers for all antisolvents except one (namely butanol, for which
the minimum total cost is achieved for three crystallisers), while
E-factors continue to improve, albeit with diminishing returns as
the total number of COBC crystallisers increases. The computed
optimal COBC crystalliser volumes are heavily inﬂuenced by the
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eat transfer requirements: each successive COBC crystalliser is
onsistently smaller than the previous one when variable size is
llowed, for all candidate solvents and all COBC conﬁgurations
tudied. The formulation and solution of an NLP optimisation model
or total continuous COBC crystallisation cost minimisation illus-
rates how the implementation of established process systems
ngineering methodologies can catalyse the development of novel
PM ﬂowsheets and plants, with simultaneous consideration and
uantiﬁcation of critical performance characteristics (such as the
nvironmental impact, here monitored via the E-factor) towards
etermining and constructing optimised CPM solutions of superior
echnical performance and guaranteed economic viability.
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